This episode delves into the specifics of Phase 2 trial design, emphasizing the critical role of clinical endpoints in assessing a drug's efficacy. We discuss the importance of control groups, randomization, and blinding in minimizing bias and ensuring the reliability of the results. The different types of endpoints, including hard clinical endpoints like overall survival and surrogate endpoints like tumor shrinkage, are explained with real-world examples. The concept of statistical power, the probability of detecting a real effect if one exists, and how it relates to sample size is also explored. The episode aims to provide listeners with a deeper understanding of how researchers determine whether a drug is showing promise in treating a specific condition.

Furthermore, the episode explores the regulatory landscape surrounding Phase 2 trial ...